Please assess the completion status of the following clinical trial:

Trial Title: GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical indication for coronary angiography~* Subjects already taking statin therapy, niacin or ezetimibe at screening must have been on a stable dose for at least 4 weeks prior to screening LDL-C. Subjects not taking lipid-regulating therapy must enter the study via a lipid stabilization period. Subjects who are intolerant to statins must meet statin intolerance entry criteria~* Fasting LDL-C ≥ 80 mg/dL (2.07 mmol/L) with or without additional risk factors, or, LDL-C ≥ 60 -\< 80 mg/dL (1.55-2.07 mmol/L) in the presence of one major or three minor risk factors~Subjects must meet the following criteria at the qualifying coronary catheterization procedure:~* Evidence of coronary heart disease (at least one lesion in a native coronary artery that has \> 20% reduction in lumen diameter) or prior percutaneous intervention (PCI)~* Left main coronary artery \< 50% reduction in lumen diameter by visual estimation~* Target coronary artery for IVUS must be accessible to the IVUS catheter, must not have a \> 50% reduction in lumen diameter within the target segment (and at least 40 mm in length); cannot have undergone prior PCI or coronary artery bypass graft (CABG) and is not a candidate for intervention over the next 18 months. It may not be a bypass graft, bypassed vessel or culprit vessel for previous myocardial infarction (MI).~Exclusion Criteria:~* Coronary artery bypass graft surgery \< 6 weeks prior to the qualifying IVUS~* New York Heart Association (NYHA) III or IV heart failure, or last known left ventricular ejection fraction less than 30%~* Uncontrolled cardiac arrhythmia that is not controlled by medications in the 3 months prior to randomization~* Known hemorrhagic stroke~* Uncontrolled hypertension at randomization~* Fasting Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at screening~* Type 1 diabetes or poorly controlled type 2 diabetes (hemoglobin A1c \[HbA1c\] \> 9%) at screening.~* Moderate to severe renal dysfunction (estimated glomerular filtration rate \[eGFR\] \< 30 ml/min/1.73m²) at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo to evolocumab administered by subcutaneous injection once a month for 76 weeks.
- Evolocumab (Type: EXPERIMENTAL): Participants received 420 mg evolocumab administered by subcutaneous injection once a month for 76 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).